Apr 18 |
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
|
Apr 16 |
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
|
Apr 4 |
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
|
Mar 20 |
InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq
|
Mar 20 |
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
|
Feb 23 |
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
|
Feb 22 |
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
|
Feb 13 |
InMed Pharmaceuticals GAAP EPS of -$0.19, revenue of $1.24M beats by $0.12M
|
Feb 13 |
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
|
Feb 9 |
InMed Pharmaceuticals announces appointment of Netta Jagpal as CFO
|